Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | hypothetical protein, conserved | 0.0353 | 0.5761 | 1 |
Echinococcus granulosus | ubiquinone biosynthesis monooxygenase COQ6 | 0.0353 | 0.5761 | 0.5761 |
Mycobacterium ulcerans | hypothetical protein | 0.0353 | 0.5761 | 0.5 |
Mycobacterium ulcerans | FAD-linked oxidoreductase | 0.0353 | 0.5761 | 0.5 |
Schistosoma mansoni | sodium/chloride dependent transporter | 0.0537 | 1 | 1 |
Echinococcus multilocularis | ubiquinone biosynthesis monooxygenase COQ6 | 0.0353 | 0.5761 | 0.5761 |
Loa Loa (eye worm) | hypothetical protein | 0.0353 | 0.5761 | 0.5761 |
Toxoplasma gondii | FAD binding domain-containing protein | 0.0353 | 0.5761 | 1 |
Chlamydia trachomatis | monooxygenase | 0.0353 | 0.5761 | 1 |
Mycobacterium ulcerans | FAD-dependent oxidoreductase | 0.0353 | 0.5761 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0537 | 1 | 1 |
Trypanosoma cruzi | Monooxygenase, putative | 0.0353 | 0.5761 | 0.5 |
Treponema pallidum | sodium- and chloride- dependent transporter | 0.0104 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0353 | 0.5761 | 0.5 |
Schistosoma mansoni | sodium/chloride dependent transporter | 0.0537 | 1 | 1 |
Echinococcus multilocularis | sodium and chloride dependent glycine | 0.0537 | 1 | 1 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0353 | 0.5761 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0353 | 0.5761 | 0.5 |
Echinococcus granulosus | sodium and chloride dependent glycine | 0.0537 | 1 | 1 |
Onchocerca volvulus | 0.0104 | 0 | 0.5 | |
Onchocerca volvulus | 0.0104 | 0 | 0.5 | |
Schistosoma mansoni | hypothetical protein | 0.0353 | 0.5761 | 0.5761 |
Wolbachia endosymbiont of Brugia malayi | 2-polyprenyl-6-methoxyphenol 4-hydroxylase | 0.0353 | 0.5761 | 0.5 |
Echinococcus multilocularis | protein MICAL 3 | 0.0353 | 0.5761 | 0.5761 |
Mycobacterium ulcerans | oxidoreductase | 0.0353 | 0.5761 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0537 | 1 | 1 |
Schistosoma mansoni | monoxygenase | 0.0353 | 0.5761 | 0.5761 |
Mycobacterium leprae | possibleputative FAD-linked oxidoreductase | 0.0353 | 0.5761 | 0.5 |
Plasmodium falciparum | FAD-dependent monooxygenase, putative | 0.0353 | 0.5761 | 1 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0353 | 0.5761 | 0.5 |
Echinococcus granulosus | protein MICAL 3 | 0.0353 | 0.5761 | 0.5761 |
Plasmodium vivax | FAD-dependent monooxygenase, putative | 0.0353 | 0.5761 | 1 |
Echinococcus granulosus | sodium and chloride dependent glycine | 0.0537 | 1 | 1 |
Onchocerca volvulus | 0.0104 | 0 | 0.5 | |
Toxoplasma gondii | FAD binding domain-containing protein | 0.0353 | 0.5761 | 1 |
Trypanosoma brucei | Monooxygenase, putative | 0.0353 | 0.5761 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0353 | 0.5761 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0353 | 0.5761 | 0.5 |
Echinococcus multilocularis | sodium and chloride dependent glycine | 0.0537 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0353 | 0.5761 | 0.5 |
Onchocerca volvulus | 0.0104 | 0 | 0.5 | |
Loa Loa (eye worm) | Sodium:neurotransmitter symporter family protein | 0.0537 | 1 | 1 |
Mycobacterium ulcerans | membrane-associated oxidoreductase | 0.0353 | 0.5761 | 0.5 |
Mycobacterium ulcerans | oxidoreductase | 0.0353 | 0.5761 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0353 | 0.5761 | 0.5 |
Trypanosoma brucei | kynurenine 3-monooxygenase, putative | 0.0353 | 0.5761 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0353 | 0.5761 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0353 | 0.5761 | 0.5 |
Mycobacterium ulcerans | oxidoreductase GMC-type | 0.0353 | 0.5761 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 60.22 uM | Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay | ChEMBL. | 22542958 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.